
7
Octopus AIM VCT plc Annual report 2023
Call us on 0800 316 2295
Portfolio activity
Having made four qualifying investments at a total cost of
£2.4 million in the first half of the year, we added a further
four qualifying investments totalling £2.5 million in the second
half. This made a total investment of £4.9 million in qualifying
investments for the year, a decrease on last year’s £21.6 million.
However, it should be pointed out that FY2022 had represented
a record year for deployment, with a large selection of existing
and new companies turning to public markets to strengthen their
balance sheets as we came out of the covid pandemic.
In the first half of the year we made four qualifying investments;
three were follow-ons into Oberon Investments Group plc, The
British Honey Company and Verici Dx plc, and one was a new
investment, Equipmake Holdings plc. In the second half, we
invested in two new companies and two existing investments. We
invested £0.4 million into Northcoders Group plc, a Manchester-
based provider of training programmes for software coding. The
funds raised will be used to expand the list of courses oered to
individuals, to include Cyber Security and Platform Engineering,
among others. The company has an exciting opportunity to form
a meaningful part of the upskilling agenda across the UK. We
invested £1.6 million into Itaconix plc, which is a leading producer
of plant-based additives for a range of consumer products, from
detergents to shampoos. Itaconix’s natural polymers help to
decarbonise products, whilst providing improved performance,
safety and sustainability. The company raised a total of
£10.5 million in a heavily over-subscribed share placing, which will
be used to support a range of growth initiatives, including the
development of new products and applications for its technology.
We invested a further £0.3 million into Intelligent Ultrasound
Group plc, the ‘classroom-to-clinic’ provider of training and
AI-enabled medical simulation products. The company raised
£5.2 million, which will support the ongoing development
of several tech-enabled products which assist ultrasound
practitioners and vastly improve the eciency of the scanning
process. We invested a further £0.2 million into Equipmake, the
electric drivetrain specialists focusing on retrofitting carbon-
intensive vehicles and aeroplanes, most notably diesel buses.
The company had its IPO in July 2022, and successfully raised a
further £6.2 million in January 2023, expanding its shareholder
base. We opted to make a small further investment given the
exciting progress the team are making.
During the year we took profits in several holdings. We sold part
of our holdings in Advanced Medical Solutions, Next 15 Group
and WANdisco. Two holdings, Clinigen Group and TP Group,
were subject to successful cash takeover bids, Clinigen at a profit
though frustratingly TP Group was at a substantial loss. We also
fully exited from investments in Diurnal, Merit Group, Synairgen
and Midatech, and sold our non-qualifying position in Tasty.
In all, disposals made a £0.5 million loss over original cost and
generated £2.5 million of cash proceeds.
Non-qualifying investments are used to manage liquidity while
awaiting new qualifying investment opportunities. Although we
still hold some existing non-qualifying AIM holdings where we see
the opportunity for further share price progress, we continued
to reduce some of these holdings in the year under review. In the
year under review £0.8 million was invested into the FP Octopus
Micro Cap Growth Fund, £0.7 million into the FP Octopus Multi
Cap Income Fund and £0.4 million into the FP Octopus Future
Generation Fund at lower share prices than our previous
investments. Recent adverse market conditions meant that these
funds had a negative impact on returns in the year although we
believe they are well positioned to have a positive impact once
the investment environment improves. The balance of the cash
is now held in two money market funds to earn a better return
as VCTs are not permitted to earn significant amounts of interest
on bank deposits.
Liquidity
The issue of liquidity within investment funds has remained a topic
of discussion this year. Shareholders may be interested to know
that at the year end 66.6% of the Company’s net assets were
held in individual quoted shares, 6.1% were held in unquoted single
company investments and 27.7% were held in cash or collective
investment funds providing short-term liquidity. Shareholders
should be aware that a proportion of the quoted holdings may
have limited liquidity owing to the size of the investee company
and the overall proportion held by the Company.
VCT regulations
There have been no further changes to the VCT regulations since
the publication of the previous set of audited accounts. The key
requirements are that 30% of funds raised should be invested in
qualifying holdings within 12 months of the end of the accounting
period in which the shares were issued, and the Company has to
maintain a minimum of 80% of the portfolio (at cost) invested in
qualifying holdings. We are determined to maintain a threshold
of quality and to invest where we see the potential for returns
from growth. Over time there has been a gradual change to the
profile of the portfolio towards earlier-stage companies, although
we continue to hold the larger market capitalisation companies,
in which we invested several years ago as qualifying companies,
or which we bought in the market prior to the rule changes,
where we see the potential for them to continue to grow.
In order to qualify, companies must:
• have fewer than 250 full-time equivalent employees;
• have less than £15 million of gross assets at the time of
investment and no more than £16 million immediately post
investment;
• be less than seven years old from the date of their first
commercial sale (or ten years if a knowledge intensive
company) if raising State Aided (i.e. VCT) funds for the first
time;
• have raised no more than £5 million of State Aided funds
in the previous 12 months and less than the lifetime limit of
£12 million (or £10 million in 12 months and a £20 million
lifetime limit if a knowledge intensive company); and
• produce a business plan to show that the funds are being
raised for growth and development.